Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Chlorpromazine HCl 100mg Tablets
NCT06154434Phase 1Completed
- Sponsor
- WhanIn Pharm
- Start
- Dec 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Aminazin in schizophrenia and psychotic disorders (2 arms), sponsored by WhanIn Pharm. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration up to 72 hours and Maximum Plasma Concentration up to 72 hours. Started Dec 2018; status: completed.
02
Drugs
Aminazin
03
Conditions
schizophreniapsychotic disorders
Beyond the preview
Go deeper on NCT06154434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06154434.